{"id":1173173,"date":"2026-08-27T23:45:15","date_gmt":"2026-08-27T23:45:15","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1173173\/"},"modified":"2026-08-27T23:45:15","modified_gmt":"2026-08-27T23:45:15","slug":"newly-approved-drug-is-a-game-changer-for-stage-4-pancreatic-cancer-patients-central-oregon-daily","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1173173\/","title":{"rendered":"Newly approved drug is a "game changer" for Stage 4 pancreatic cancer patients – Central Oregon Daily"},"content":{"rendered":"
    \n
  1. Newly approved drug is a “game changer” for Stage 4 pancreatic cancer patients<\/a>  Central Oregon Daily<\/li>\n
  2. FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer<\/a>  BBC<\/li>\n
  3. FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease<\/a>  WSJ<\/li>\n
  4. As RevMed preps for \u2018historic\u2019 pancreatic cancer launch, questions linger on the ground<\/a>  Fierce Pharma<\/li>\n
  5. FDA Approves RevMed\u2019s Breakthrough Pill for Pancreatic Cancer<\/a>  Bloomberg.com<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"Newly approved drug is a “game changer” for Stage 4 pancreatic cancer patients  Central Oregon Daily FDA approves breakthrough…\n","protected":false},"author":2,"featured_media":1173174,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4315],"tags":[1204,294773,105,4326,318157,1408,11615,16,15],"class_list":["post-1173173","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-cancer","tag-daraxonrasib","tag-health","tag-medication","tag-pancreatic","tag-therapy","tag-treatment","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117170138624099981","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1173173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1173173"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1173173\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1173174"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1173173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1173173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1173173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}